Vaccines

La E, Singer D, Dubois de Gennes C, Graham J, Grace M, Poston S, Verelst F. Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination in US adults aged 60 years with cardiopulmonary disease. Poster presented at the ISPOR 2025; May 15, 2025. Montreal, Canada.


OBJECTIVES: Risk of severe respiratory syncytialvirus (RSV) disease is increased among adults with cardiopulmonary disease. This study modeled the public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination in US adults ≥60 years of age (YOA) with specific prevalent cardiopulmonary diseases.

Singer D, La E, Dubois de Gennes C, Graham J, Grace M, Biundo E, Poston S, Verelst F. Modeled public health impact of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years at increased risk for severe RSV disease in the United States over 5 years. Poster presented at the 13th International Respiratory Syncytial Virus (RSV) Symposium; March 12, 2025. Iguazu Falls, Brazil.


Abstract not available at this time.

Verelst F, La E, Singer D, Graham J, Grace M, Biundo E, Poston S. Modelled public health impact of adjuvanted RSVPreF3 vaccination in adults aged 60 years and older in the United States over 5 years. Poster presented at the 13th International Respiratory Syncytial Virus (RSV) Symposium; March 12, 2025. Iguazu Falls, Brazil.


Abstract not available at this time.

Buck P, Graham J, Grace M, Myers E, Diaz-Decaro J. Public health impact of vaccination strategies in 16-to-40-year-old females for the prevention of CMV and congenital CMV in the United States. Poster presented at the European Congenital Cytomegalovirus Initiative (ECCI) 2024; October 9, 2024. Leiden, The Netherlands. Previously presented at the European Society for Paediatric Infectious Diseases (ESPID) 2024.


Nardoni V, Lippi M, Marinai S, Hyeraci G, Maccari M, Arana A, Lucenteforte E, Limoncella G, Mohammadi S, Roberto G, Dehghan Tarazjani A, Virgili G, Weibel D, Gini R. Comparing humans and large language models in filling clinical questionnaires. Presentation to be given at the 4th International Conference Series on Hybrid Human-Artificial Intelligence; June 9, 2025. Pisa, Italy.


Abstract not available at this time.

George S, Carrico J, Hicks KA, Loukov D, Ng C, Curran D. Cost-effectiveness and public health impact of recombinant zoster vaccine versus no herpes zoster vaccination in selected populations of immunocompromised adults in Canada. BMC Health Serv Res. 2025 Apr 25;25(1):604. doi: 10.1186/s12913-025-12550-x


La EM, Sweeney C, Davenport E, Bunniran S. Pharmacy and healthcare provider offices as convenient adult vaccination settings in the US: Patient experiences from a survey of recently-vaccinated adults. Vaccine. 2025 Apr 8;54:127057. doi: 10.1016/j.vaccine.2025.127057


Layton JB, Lloyd PC, Peetluk LS, Jiao Y, Djibo DA, Gruber JF, Deng J, Bui C, Lo AC, Ogilvie RP, Parambi R, Miller M, Song J, Weatherby LB, Cho S, Wong HL, Clarke TC, Hervol JR, Illei D, Bell EJ, Yang GW, Seeger JD, Wernecke M, Richey MM, Forshee RA, Anderson SA, Chillarige Y, McMahill-Walraven CN, Amend KL, Anthony MS, Shoaibi A. Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States. PLoS One. 2025 May 6;20(5):e0320434. doi: 10.1371/journal.pone.0320434


Horn EK, La EM, Bektas M, Khan S, Gerber SI. Disparities in respiratory syncytial virus risk factors, diagnosis, and outcomes in adults by race, ethnicity, and other social determinants of health in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Apr;25(4):459-71. doi: 10.1080/14737167.2024.2441867


INTRODUCTION: Respiratory syncytial virus (RSV) vaccination could improve health equity by protecting individuals who are disproportionally at increased risk of RSV infection and severe RSV-related outcomes. However, limited information is available about RSV-related disparities among United States (US) adults.

Barbieri M, Talbird S, Carrico J, Boccalini S, Bencina G, Bonanni P, Mellott CE, Senese F, Lang JC, Bechini A. Public health impact and return on investment of the pediatric National Immunization Program in Italy. Expert Rev Vaccines. 2024 Dec;23(1):974-85. doi: 10.1080/14760584.2024.2411425


OBJECTIVES: We conducted a cost-benefit analysis of the pediatric National Immunization Program (NIP) in Italy.

Subscribe to Vaccines

How Can We Help You?